Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2959 Target Snapshot

Tyrosine-protein kinase ITK/TSK · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
3,410Compounds
539Assays
15Approved Drugs
3,439.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Tyrosine-protein kinase ITK/TSK shows approved-linked disease relevance led by chromophobe renal cell carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q08881. Start with chromophobe renal cell carcinoma, then reuse UniProt Q08881 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with chromophobe renal cell carcinoma, then reuse UniProt Q08881 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
chromophobe renal cell carcinoma

Tyrosine-protein kinase ITK/TSK shows approved-linked disease relevance led by chromophobe renal cell carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with chromophobe renal cell carcinoma because it currently carries approved-linked support. Linked drugs include PAZOPANIB HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase ITK/TSK as ChEMBL target CHEMBL2959, mapped to UniProt Q08881. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tyrosine-protein kinase ITK/TSK
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2959
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q08881
Tyrosine-protein kinase ITK/TSK
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Tyrosine-protein kinase ITK/TSK is the right protein anchor across sources, using UniProt Q08881 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why chromophobe renal cell carcinoma is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameTyrosine-protein kinase ITK/TSK
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ08881
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTyrosine-protein kinase ITK/TSK
UniProt AccessionQ08881
Component TypeProtein
Sequence Length620 aa

Tyrosine-protein kinase ITK/TSK

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Tyrosine-protein kinase ITK/TSK, mapped to UniProt Q08881. Sequence length is 620 aa.

Mapped IDQ08881
Review nameTyrosine-protein kinase ITK/TSK
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Tyrosine-protein kinase ITK/TSK shows approved-linked disease relevance led by chromophobe renal cell carcinoma. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
chromophobe renal cell carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugPAZOPANIB HYDROCHLORIDE
Approved-linked Approved
clear cell renal carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugPAZOPANIB HYDROCHLORIDE
Approved-linked Approved
collecting duct carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugPAZOPANIB HYDROCHLORIDE
Approved-linked Approved
papillary renal cell carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugPAZOPANIB HYDROCHLORIDE
Approved-linked Approved
renal cell carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugPAZOPANIB HYDROCHLORIDE
Approved-linked Approved
sarcoma
1 linked drug · 1 direct · 1 efficacy
Linked drugPAZOPANIB HYDROCHLORIDE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with chromophobe renal cell carcinoma because it currently carries approved-linked support. Linked drugs include PAZOPANIB HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasechromophobe renal cell carcinoma
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

15
Approved
7
Phase III
20
Phase II
5
Phase I
Assay Mix

Activity Type Distribution

IC502,471.0
KI799.0
EC5025.0
KD144.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5913558 10.4 IC50 0.04 Preclinical
CHEMBL5945729 10.3 IC50 0.05 Preclinical
CHEMBL5878223 10.1 IC50 0.08 Preclinical
CHEMBL3426309 10.05 Ki 0.09 Preclinical
CHEMBL5751446 10.05 IC50 0.09 Preclinical
CHEMBL5778702 10.05 IC50 0.09 Preclinical
CHEMBL3263053 10.0 Ki 0.1 Preclinical
CHEMBL5822312 10.0 IC50 0.1 Preclinical
CHEMBL3355737 9.77 Ki 0.17 Preclinical
CHEMBL2441275 9.7 Ki 0.1995 Preclinical
Distribution

pChEMBL Value Distribution

89
5.0
145
5.5
334
6.0
235
6.5
435
7.0
261
7.5
240
8.0
120
8.5
80
9.0
20
9.5
pChEMBL
Approved Drugs

Approved Drugs

RITLECITINIB
CHEMBL4085457
Approved 2023
Properties Compare Identifier
ZANUBRUTINIB
CHEMBL3936761
Approved 2019
Properties Compare Identifier
FEDRATINIB
CHEMBL1287853
Approved 2019
Properties Compare Identifier
NINTEDANIB
CHEMBL502835
Approved 2014
Properties Compare Identifier
IBRUTINIB
CHEMBL1873475
Approved 2013
Properties Compare Identifier
SUNITINIB
CHEMBL535
Approved 2006
Properties Compare Identifier
DASATINIB
CHEMBL5416410
Approved 2006
Properties Compare Identifier
Assay Landscape

Assay Landscape

539
Total Assays
1,448
Tested Compounds
3
Assay Types
Binding — 523 assays, 1,448 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 410 1,139 7.3
cell-based format 57 166 6.6
assay format 56 143 6.8
Functional — 10 assays, 169 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 7 55 6.7
assay format 3 114 6.7
ADME — 6 assays, 6 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 3 4 7.6
cell-based format 2 2 6.3
assay format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine